Isabelle Chabot
Overview
Explore the profile of Isabelle Chabot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lenderking W, Savva Y, Atkinson M, Campbell R, Chabot I, Moline M, et al.
J Patient Rep Outcomes
. 2024 Jul;
8(1):65.
PMID: 38951287
Background: The Insomnia Severity Index (ISI) is a widely used measure of insomnia severity. Various ISI research findings suggest different factor solutions and meaningful within-individual change (MWIC) to detect treatment...
2.
Ndirangu K, Chabot I, Lewis K, Lambert A, Zhao Q, Lucero M, et al.
Future Oncol
. 2024 Jun;
20(25):1807-1824.
PMID: 38861292
To report treatment patterns and quality of life (QoL) in HER2-negative advanced breast cancer patients. Data were drawn from a cross-sectional survey in Europe and USA. Hormone plus targeted therapy...
3.
Turcotte C, Fenelon-Dimanche R, Lemiere C, Beauchesne M, Abou-Atme B, Chabot I, et al.
Explor Res Clin Soc Pharm
. 2022 Sep;
7:100167.
PMID: 36051610
Background: Achieving asthma control is often difficult, despite the availability of effective medications. Because of their expertise, regular contact with patients, and accessibility, community pharmacists can play an important role...
4.
Marineau A, St-Pierre C, Lessard-Hurtubise R, David M, Adam J, Chabot I
J Oncol Pharm Pract
. 2022 Jun;
29(5):1144-1153.
PMID: 35642282
Background: Outpatients treated with oral anti-cancer drugs, including selective cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), may benefit from a pharmacy practice setting adapted to support proper oral anti-cancer drug monitoring. This...
5.
Campbell R, Chabot I, Rousseau B, Bridge D, Nicol G, Meier G
Int J Neurosci
. 2021 Oct;
133(8):864-878.
PMID: 34668828
Study Objective: The objective of this study was to define and characterize the unmet needs in the pharmacological management of insomnia. Methods: A systematic literature review was conducted to identify...
6.
Omar R, Leboeuf M, Lemyre M, Chabot I, Trottier S, Ulmann A, et al.
J Obstet Gynaecol Can
. 2021 Oct;
44(2):175-181.
PMID: 34656768
Objectives: To evaluate the spermicidal efficacy of non-hormonal vaginal gel in vitro and in a post-coital test, and to evaluate its contraceptive efficacy in Canadian women of childbearing age. Methods:...
7.
Zhao Q, Hughes R, Neupane B, Mickle K, Su Y, Chabot I, et al.
BMC Cancer
. 2021 Jul;
21(1):758.
PMID: 34193107
Background: Eribulin mesylate (ERI; Halaven®) is a microtubule inhibitor approved in the United States for metastatic breast cancer patients with at least two prior chemotherapy regimens for metastatic breast cancer,...
8.
Trigg A, Brohan E, Cocks K, Jones A, Tahami Monfared A, Chabot I, et al.
Epilepsy Behav
. 2021 Apr;
118:107938.
PMID: 33839450
Rationale: Study 311 (E2007-G000-311; NCT02849626) was a Phase 3, multicenter, open-label single-arm study of adjunctive perampanel oral suspension in pediatric patients (aged 4 to <12 years) with partial-onset seizures (POS)...
9.
Chabot I, Zhao Q, Su Y
Curr Med Res Opin
. 2020 Oct;
36(12):2025-2036.
PMID: 33044090
Background: Eribulin mesylate (eribulin) is indicated for patients with metastatic breast cancer (MBC) who have previously received at least two chemotherapies in the US and for patients with locally advanced...
10.
Raymond F, Ouameur A, Deraspe M, Iqbal N, Gingras H, Dridi B, et al.
ISME J
. 2015 Sep;
10(3):707-20.
PMID: 26359913
Microbiome studies have demonstrated the high inter-individual diversity of the gut microbiota. However, how the initial composition of the microbiome affects the impact of antibiotics on microbial communities is relatively...